Lin BioScience, Inc.

6696

TW0006696008

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
92.9 ^TWD	-3.03%		-5.59%	-18.51%

04-23	Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 23, 2024 at 07:05 am

Lin BioScience, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was TWD 687.19 million compared to TWD 313.52 million a year ago. Basic loss per share from continuing operations was TWD 9.29 compared to TWD 4.37 a year ago.

Latest news about Lin BioScience, Inc.

Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-23	CI
Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	14/08/23	CI
Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23	CI
Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	12/08/22	CI
Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	25/04/22	CI
Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	14/08/21	CI
Lin Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	06/05/21	CI
Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	08/04/21	CI
Lin BioScience, Inc.(GTSM:6696) added to S&P Global BMI Index	21/09/20	CI
Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	13/08/20	CI
Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	29/04/20	CI
Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	13/08/19	CI
Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	25/04/19	CI
US Food and Drug Administration Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease	17/09/18	CI

Chart Lin BioScience, Inc.

Duration

Period

More charts

Company Profile

LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIN BIOSCIENCE, INC.	-18.51%	225M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B